Blood Cancer Clinical Trials
A listing of Blood Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 5 clinical trials
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations (DETERMINE)
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.Capmatinib …
- 0 views
- 03 Jul, 2025
- 16 locations
ATRA and Carfilzomib in Plasma Cell Myeloma Patients (ATRA)
all hematologic malignancies. Over the past 30 years the global prevalence of multiple myeloma has risen to 126%, with 85% of diagnoses occurring in patients >55 years of age. In the past 15 years
- 0 views
- 25 Jun, 2025
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.The names of the study drugs involved in this study are:Iberdomide (a type of cereblon E3 ligase modulator)Elotuzumab (a type of monoclonal antibody)Dexamethasone (a type …
- 0 views
- 03 Jul, 2025
- 1 location
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- 0 views
- 03 Jul, 2025
- 16 locations
A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to …
- 0 views
- 03 Jul, 2025
- 9 locations